Adaptimmune Therapeutics plc

First Preclinical Data from Adaptimmune’s Mesothelin HiT Program at ASGCT Demonstrate Antigen-specific Tumor Cell Killing in vitro and Complete Tumor Regression in an Animal Model

Latest Presentation Press Release

< >

Adaptimmune Reports First Quarter Financial Results and Business Update

Webcast Press Release

< >

We will present data from our Phase 2 SPEARHEAD-1 clinical trial for people with synovial sarcoma

Learn More

< >

Check out our open vacancies!

Learn More

< >

Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT

Click Here Latest Corporate Deck

< >

Q4 and Full Year 2020 Business and Financial Update

Click Here Latest Presentation

< >

Certified Best Place to Work-US and Great Place to Work-UK. Visit our Careers page to join our growing team

Careers

< >

Adaptimmune’s mission is to transform the lives of people with cancer by designing and delivering cell therapies

Learn More

< >

Our Clinical Trials

Advancing T-cell therapy through world-class expertise

Our main priority at Adaptimmune is to improve the outcomes of patients who are suffering from cancer via immunotherapy.

View Our Clinical Trials

For Patients and Families

Helpful resources for patients and their families

Our efforts in immunotherapy are aimed at improving outcomes for patients who are living with cancer. Our resources are available to both patients their families.

View Our Resources

Our Pipeline

SPEAR-heading the Cancer Revolution

An industry leading TCR pipeline that targets solid tumors

We build affinity-enhanced T-cell therapies aimed at destroying cancer cells. Our therapies work with the immune system to improve the detection and targeting of those cancer cells.

View Our Pipeline

Our Robust Manufacturing Process

Delivering affinity-enhanced TCRs to patients

Our manufacturing process provides world class capabilities for designing and delivering cell which enables us to efficiently supply patients in our clinical trials.

Learn More

First Preclinical Data from Adaptimmune’s Mesothelin HiT Program at ASGCT Demonstrate Antigen-specific Tumor Cell Killing in vitro and Complete Tumor Regression in an Animal Model

Adaptimmune Reports First Quarter Financial Results and Business Update

We will present data from our Phase 2 SPEARHEAD-1 clinical trial for people with synovial sarcoma

Check out our open vacancies!

Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT

Q4 and Full Year 2020 Business and Financial Update

Certified Best Place to Work-US and Great Place to Work-UK. Visit our Careers page to join our growing team

Adaptimmune’s mission is to transform the lives of people with cancer by designing and delivering cell therapies

Our Clinical Trials

Advancing T-cell therapy through world-class expertise

For Patients and Families

Helpful resources for patients and their families

Our Pipeline

SPEAR-heading the Cancer Revolution

An industry leading TCR pipeline that targets solid tumors

Our Robust Manufacturing Process

Delivering affinity-enhanced TCRs to patients

Latest News

First Preclinical Data from Adaptimmune’s Mesothelin HiT Program at ASGCT Demonstrate Antigen-specific Tumor Cell Killing in vitro and Complete Tumor Regression in an Animal Model